Veterans Affairs Medical Center - Memphis

Summary

Veterans Affairs Medical Center - Memphis is a medical facility located in Memphis, Tennessee. This center is recognized for care of Lung Cancer, Prostate Cancer, Leukemia, Colon Cancer, Colorectal Cancer and other specialties. Veterans Affairs Medical Center - Memphis is involved with conducting 92 clinical trials across 151 conditions. There are 6 research doctors associated with this hospital, such as Alva B Weir, MD, George N Verne, QiQi Zhou, MD PhD, and Csaba P Kovesdy, MD.

Top PIs

Clinical Trials running at Veterans Affairs Medical Center - Memphis

Prostate Cancer

Atherosclerosis

Irritable Bowel Syndrome

Cardiovascular Disease

Mild Cognitive Impairment

Cognitive Impairment

Dementia

Lung Cancer

Cancer

Non-Small Cell Lung Cancer

High Dose Testosterone

for Prostate Cancer

This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis

Recruiting

3 awards

Phase 2

Registry

for Advanced Prostate Cancer

Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingdom (UK), and the United States (US). Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices. Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of five years. Patients will be followed prospectively for overall survival, clinically significant adverse events, comorbidities, changes in cancer treatments, and PROMs. PROMs questionnaires will be collected at enrollment and every three months thereafter. Physician Questionnaires will be collected from all participating sites at patient enrollment, time of first change in treatment and/or one year follow-up, at each subsequent change of treatment, and discontinuation of treatment. As such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs for men with mHSPC and M0/M1 CRPC. By collecting blood at enrollment, time of first change in treatment and/or one year follow-up (plasma, cell free DNA, buffy coat / RNA), this registry will further identify and validate molecular phenotypes of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen at each subsequent change in treatment due to progression of disease. When feasible, existing tumor tissue may be collected for correlation with described blood based studies. All samples will be used for future research. This cohort study will provide the research community with a unique biorepository to identify biomarkers of treatment response and resistance.

Recruiting

1 award

N/A

5 criteria